List

(18) Man KF*, Darweesh O*, Hong J*, Thompson A, O’Connor C, Bonaldo C, Melkonyan MN, Sun M, Patel R, Ellisen L, Robinson T, Song D, Koh SB+. 2025. CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance. Oncogene. PDF​ ; Blog

​

(17) Wang Y*, Gao B*, Zhang L, Wang X, Zhu X, Yang H, Zhang F, Zhu X, Zhou B, Yao S, Nagayama A, Lee S, Ouyang J, Koh SB, Eisenhauer EL, Zarrella D, Lu K, Rueda BR, Zou L, Su XA, Yeku O, Ellisen LW, Wang XS, Lan L+. 2024. Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature Communications. PDF

​

(16) Koh SB+. 2022. The expanding role of WEE1. Cellular Signalling. PDF

​

(15) Koh SB, Ellisen LW+. 2021. Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer Cell. PDF

​

(14) Kalantar-Motamedi Y*, Choi RJ*, Koh SB, Bramhall JL, Fan TP, Bender A+. 2021. Prediction and identification of synergistic compound combinations against pancreatic cancer cells. iScience. PDF

 

(13) Koh SB*, Dontchos B*, Bossuyt V*, Edmonds C, Cristea S, Melkonjan N, Mortensen L, Ma A, Beyerlin K, Denault E, Niehoff E, Hirz T, Sykes DB, Michor F, Specht M, Lehman C, Ellisen LW, Spring LM+. 2021. Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. npj Precision Oncology. PDF

 

(12) Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW+. 2021. RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer. Clinical Cancer Research. PDF

 

(11) Qiao S*, Koh SB*, Vivekanandan V, Salunke D, Patra KC, Zaganjor E, Ross K, Mizukami Y, Jeanfavre S, Chen A, Mino-Kenudson M, Ramaswamy S, Clish C, Haigis M, Bardeesy N, Ellisen LW+. 2020. REDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors. Genes & Development. #Cover mention. PDF

​

(10) Koh SB+. 2019. Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent. Journal of Biological Chemistry. PDF

​

(9) Wallez Y+, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, de Quirós Fernández SB, Lau A, Richards FM+, Jodrell DI. 2018. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular Cancer Therapeutics. PDF

 

(8) Koh SB+, Wallez Y, Dunlop CR, de Quirós Fernández SB, Bapiro TE, Richards FM, Jodrell DI. 2018. Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. Cancer Research. #Issue highlight. PDF

​

(7) Jackson RC, Veroli GY+, Koh SB, Goldlust I, Richards FM, Jodrell DI. 2017. Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy. PLoS Computational Biology. PDF

 

(6) Grah JS+, Harrington JA, Koh SB, Pike JA, Schreiner A, Burger M, Schönlieb CB, Reichelt S. 2017. Mathematical imaging methods for mitosis analysis in live-cell phase contrast microscopy. Methods. PDF

 

(5) Koh SB+, Mascalchi P, Rodriguez E, Lin Y, Jodrell DI, Richards FM+, Lyons SK. 2017. A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level. Journal of Cell Science. PDF ; Addgene

​

(4) Veroli GY+, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, Richards F, Jodrell DI. 2015. An automated fitting procedure and software for dose-response curves with multiphasic features. Scientific Reports. PDF

 

(3) Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM+, Jodrell DI. 2015. CHK1 inhibition synergizes with gemcitabine by initially destabilizing the DNA replication apparatus. Cancer Research. PDF

​

(2) Tan KL, Koh SB, Ee RP, Khan M, Go ML+. 2012. Curcumin analogues with potent and selective anti-proliferative activity on acute promyeolocytic leukaemia: Involvement of accumulated misfolded nuclear receptor co-repressor protein as a basis for selective activity. ChemMedChem. PDF

​

(1) Yeo WK, Tan KL, Koh SB, Khan M, Nilar S, Go ML+. 2012. Exploration and optimisation of structure-activity relationships in drug design using the Taguchi Method. ChemMedChem. PDF